Alexion Value Stock - Dividend - Research Selection
Market price: 182,50 USD
Alexion Pharmaceuticals Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||3.002.900.000|
|Free cash flow||2.896.199.936|
|Liabilities & Shareholders equity||18.103.000.000|
|Diluted shares outstanding||444.000.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||81.029.996.544,00 USD|
|Indices||MSCI World Index|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2011-05-24,2.0000/1.0000; 2011-05-23,2.0000/1.0000; 2008-08-26,2.0000/1.0000; 2008-08-25,2.0000/1.0000|
Description of the company
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.